Leading Cognitive Insights Agency Expands Oncology Capabilities Under Leadership of Meredith Jacobetz, PhD
[BRISTOL, PA] – [FEBRUARY 10, 2026] – BioVid, a leading cognitive insights agency serving the life sciences industry today, announced the launch of its Oncology Center of Excellence (CoE), a strategic initiative designed to deliver enhanced expertise and innovative solutions to clients navigating the increasingly complex oncology landscape. The new CoE will be led by Meredith Jacobetz, PhD, whose extensive oncology experience spans both client-side and supplier-side perspectives.
The Oncology CoE represents a transformative milestone for BioVid, consolidating deep therapy-area expertise, cutting-edge best practices, and forward-thinking oncology perspectives into a centralized hub. This strategic expansion will leverage BioVid’s robust, science-driven methodologies to unearth and activate critical market insights, empowering clients to make more impactful and informed decisions in the competitive cancer therapeutics space.
“The launch of our Oncology Center of Excellence reflects BioVid’s commitment to providing our clients with the specialized expertise and innovative approaches they need to succeed in one of the most dynamic and challenging therapeutic areas,” said Peggy Hirtle, BioVid CEO. “Under Meredith’s leadership, the CoE will deliver unparalleled value by combining scientific rigor with strategic insights that drive real-world impact.”
Dr. Jacobetz brings more than 20 years of oncology expertise to her role, with a proven track record of bridging scientific and commercial objectives to foster innovative partnerships. Holding a PhD in Oncology from the University of Cambridge, she possesses a comprehensive understanding of both the scientific foundations and market dynamics of cancer therapeutics. Throughout her career, Dr. Jacobetz has been recognized for her ability to align business objectives with strategic execution, consistently delivering actionable insights that drive market success.
“I’m thrilled to lead BioVid’s Oncology Center of Excellence at this pivotal moment in cancer development and commercialization,” said Dr. Jacobetz. “By bringing together our team’s collective expertise and BioVid’s proven methodologies, we’ll help our clients navigate complexity, identify opportunities and, ultimately, accelerate the delivery of innovative therapies to patients who need them most.”
The Oncology CoE will serve as a central resource for BioVid’s pharmaceutical and biotech clients, offering specialized capabilities in market research, market access, competitive intelligence, strategic planning, and insight generation across all oncology segments.
About BioVid: BioVid is a leading life science consultancy that integrates advanced behavioral science and artificial intelligence into commercial and market access strategies. BioVid helps healthcare organizations optimize customer relationships by aligning market opportunities with deep behavioral insights. Through scientifically grounded methodologies aligned with customer mindsets and designed to drive measurable outcomes, BioVid empowers clients to succeed in dynamic, competitive healthcare markets and advance global healthcare improvement.
For more information, visit www.biovid.com.